Inclusion Criteria:

   - Newly diagnosed high-grade glioma

      - Anaplastic astrocytoma

      - Glioblastomamultiforme

      - Gliosarcoma

      - Primary spinal cord malignant glioma allowed

      - No oligodendroglioma oroligoastrocytoma

   - Patient must have histological verification of diagnosis

      - No M+ disease (defined as evidence of neuraxis dissemination)

      - No positive CSF cytology

   - ECOG performance status (PS) 0-2

      - Karnofsky PS 50-100% (patients > 16 years of age)

      - Lansky PS 50-100% (patients ≤ 16 years of age)

   - ANC ≥ 1,000/μL

   - Platelet count ≥ 100,000/μL

   - Hemoglobin ≥ 8.0 mg/dL (transfusion independent)

   - Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age
   and/or gender as follows:

      - 0.4 mg/dL (1 month to < 6 months of age)

      - 0.5 mg/dL (6 months to < 1 year of age)

      - 0.6 mg/dL (1 to < 2 years of age)

      - 0.8 mg/dL (2 to < 6 years of age)

      - 1.0 mg/dL (6 to < 10 years of age)

      - 1.2 mg/dL (10 to < 13 years of age)

      - 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)

      - 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)

   - Proteinuria < 2+ OR urine; protein ratio (UPC) ≤ 0.5

      - If UPC > 0.5, a 24-hour urine protein should be obtained and level should be <
      1,000 mg of protein

   - Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

   - ALT < 2.5 times ULN

   - Serum albumin ≥ 2 g/dL

   - PT INR ≤ 1.5 times ULN

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception during all study therapy and for ≥ 6
   months after completion of bevacizumab

   - Hypertension well controlled (≤ 95^th percentile for age and height if patient is ≤
   17years) by stable doses of medication allowed

      - For patients > 17 years, systolic blood pressure (BP) ≤ 150 mm Hg or diastolic BP
      ≤ 100 mm Hg)

   - Seizure disorder allowed provided patient is well-controlled and on nonenzyme-inducing
   anticonvulsants

   - No history of myocardial infarction, severe or unstable angina, clinically significant
   peripheral vascular disease, ≥ grade 2 heart failure, or serious and inadequately
   controlled cardiac arrhythmia

   - No known bleeding diathesis or coagulopathy

   - No prior arterial thromboembolic events, including transient ischemic attacks
   orcerebrovascular accidents

   - No prior diagnosis of a deep venous thrombosis, including pulmonary embolism, and no
   known thrombophilic condition (e.g., protein S, protein C, antithrombin III
   deficiency, Factor V Leiden or Factor II G202'0A mutation, homocysteinemia, or
   antiphospholipid antibody syndrome)

   - No history of an abdominal fistula, gastrointestinal perforation, or intra-abdominal
   abscess within the past 6 months

   - No serious or non-healing wound, ulcer, or bone fracture

   - No evidence of significant postoperative intracranial hemorrhage, defined as > 1 cm of
   blood on postoperative MRI scan (potentially in addition to the postoperative scan)
   obtained within the past 14days

   - No history of allergic reaction to Chinese hamster ovary cell products or other
   recombinanthuman antibodies

   - No more than 31 days since definitive surgery

   - Must not have received any prior chemotherapy, radiotherapy, immunotherapy, or bone
   marrow transplant

   - More than 7 days since major surgical procedure and recovered

      - For patients scheduled to receive bevacizumab:

         - More than 28 days since major procedure

         - More than 14 days since intermediate procedure

         - More than 7 days since minor procedure (lumbar picture or placement of PICC
         lines are not considered minor procedures)

   - No other current anti-cancer agents

   - No concurrent nonsteroidal anti-inflammatory medications known to inhibit platelet
   function or known to selectively inhibit cyclooxygenase activity

   - No concurrent enzyme inducing anticonvulsants

   - No concurrent HDAC inhibitors (e.g., valproic acid)

   - No concurrent anticoagulants including systemic thrombolytic agents, heparin, low
   molecular weight heparins, or warfarin except as required to maintain patency of
   pre-existing permanent vascular catheters or for prevention of thrombosis in the
   post-operative period